Teva Says U.S. Attorney Investigating Marketing of Drugs
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd., the world’s biggest maker of generic medicines, said federal prosecutors in New York are investigating its sales and marketing practices for two drugs.
The U.S. attorney in Manhattan sent the Petach Tikva, Israel-based company a civil investigative demand for documents and information relating to the sales of Copaxone and Azilect from 2006 through the present, Teva said in its annual report filed today with the U.S. Securities and Exchange Commission. A spokesman said he couldn’t immediately comment further.